CITATION REPORT List of articles citing

Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension

DOI: 10.1038/hr.2014.28 Hypertension Research, 2014, 37, 507-12.

Source: https://exaly.com/paper-pdf/59200833/citation-report.pdf

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
46	Combination therapy adding tadalafil to existing ambrisentan in patients with pulmonary arterial hypertension. <i>Hypertension Research</i> , 2014 , 37, 488-9	4.7	4
45	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. <i>Global Cardiology Science & Practice</i> , 2014 , 2014, 257-90	0.7	10
44	Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. <i>Core Evidence</i> , 2015 , 10, 99-109	4.9	19
43	Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF. <i>Hypertension Research</i> , 2015 , 38, 829-39	4.7	11
42	Upregulation of canonical transient receptor potential channel in the pulmonary arterial smooth muscle of a chronic thromboembolic pulmonary hypertension rat model. <i>Hypertension Research</i> , 2015 , 38, 821-8	4.7	10
41	Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review. <i>Current Medical Research and Opinion</i> , 2015 , 31, 1793-807	2.5	12
40	Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension. <i>Hypertension Research</i> , 2015 , 38, 539-44	4.7	27
39	Beyond a single pathway: combination therapy in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2016 , 25, 408-417	9.8	38
38	Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials. <i>Chest</i> , 2016 , 150, 353-66	5.3	32
37	Ambrisentan in pulmonary arterial hypertension: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2016 , 32, 50-59	1.5	
36	Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1520-1530	3.8	39
35	Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. <i>Lancet Respiratory Medicine,the</i> , 2016 , 4, 291-305	35.1	133
34	Oral Tadalafil in Children with Pulmonary Arterial Hypertension. <i>Drug Research</i> , 2016 , 66, 7-10	1.8	14
33	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. <i>Chest</i> , 2017 , 151, 468	-48.6	57
32	Ambrisentan: a review of its use in pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2017 , 11, 233-244	4.9	12
31	Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1). <i>Respiratory Medicine</i> , 2017 , 126, 84-92	4.6	10
30	Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. <i>Pulmonary Circulation</i> , 2017 , 7, 312-325	2.7	35

(2021-2017)

29	Medical Treatment of Pulmonary Arterial Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017 , 38, 686-700	3.9	6
28	Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis. <i>Chest</i> , 2017 , 151, 90-105	5.3	31
27	Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials. <i>Patient Preference and Adherence</i> , 2017 , 11, 871-885	2.4	12
26	Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. <i>BMC Cardiovascular Disorders</i> , 2017 , 17, 239	2.3	19
25	Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database. <i>Chest</i> , 2018 , 154, 136-147	5.3	13
24	Trial Duration and Risk Reduction in Combination Therapy Trials for Pulmonary Arterial Hypertension: A Systematic Review. <i>Chest</i> , 2018 , 153, 1142-1152	5.3	3
23	Efficacy and tolerability of pharmacological interventions for pulmonary arterial hypertension: A network meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018 , 50, 1-10	3.5	5
22	A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension. <i>Drug Delivery</i> , 2018 , 25, 1898-1909	7	10
21	Ambrisentan [] tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2018 , 34, 289-299	1.5	
20	Efficacy and safety of oral targeted therapies in pulmonary arterial hypertension: a meta-analysis of randomized clinical trials. <i>Pulmonary Circulation</i> , 2018 , 8, 2045894018798183	2.7	3
19	Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis. <i>Clinical Drug Investigation</i> , 2019 , 39, 1031-1044	3.2	4
18	Treatment of pulmonary arterial hypertension: A review of drugs available for advanced therapy. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2019 , 25,	0.2	
17	Phosphodiesterase 5 inhibitors for pulmonary hypertension. <i>The Cochrane Library</i> , 2019 , 1, CD012621	5.2	32
16	Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2019 , 155, 565-586	5.3	126
15	Risk stratification and medical therapy of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	316
14	A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension. <i>Annals of Pharmacotherapy</i> , 2020 , 54, 423-433	2.9	2
13	Advanced Diagnosis and Therapy for Pulmonary Arterial Hypertension. <i>Nano LIFE</i> , 2020 , 10, 2040003	0.9	2
12	Endothelin receptor antagonists for pulmonary arterial hypertension. <i>The Cochrane Library</i> , 2021 , 3, CD	00 <u>0</u> 443	41

11	Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis. <i>Drug Delivery</i> , 2021 , 28, 1007-1019	7	2
10	Gaps and Controversies of New Treatment Recommendations in Recent Pulmonary Hypertension Guidelines: What We Know and What We Don[t. <i>Advances in Pulmonary Hypertension</i> , 2017 , 16, 20-25	0.5	
9	[A systematic review as a method of gathering scientific evidence into clinical guidelines: CHEST-2019 guideline for the therapy pulmonary arterial hypertension in adults]. <i>Terapevticheskii Arkhiv</i> , 2019 , 91, 105-114	0.9	1
8	Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review <i>JAMA - Journal of the American Medical Association</i> , 2022 , 327, 1379-1391	27.4	9
7	Riociguat in the Treatment of Pulmonary Arterial Hypertension in Mexico <i>Archives of Medical Research</i> , 2022 ,	6.6	1
6	Effects of oral targeted treatments in pulmonary arterial hypertension: A systematic review and meta-analysis. 9,		
5	Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2022 , 146, 597	'-612	O
4	Targeted therapies in patients with pulmonary arterial hypertension due to congenital heart disease. 2022 , 20,		
3	Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis. 2022 , 31, 220036		1
2	Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials. 2022 , 76, 102144		
1	Effect of Phosphodiesterase-5 (PDE-5) Inhibitors on Clinical Outcomes in Patients With Pulmonary		0